Formed in 2019, The Amyloidosis Forum has been developed through a public-private partnership between the Amyloidosis Research Consortium (ARC) and the US Food and Drug Administration (FDA). The overarching goal of the Forum is to optimize innovation and accelerate the advancement of new therapeutics by addressing scientific gaps and needs through the conduct of mutually beneficial scientific activities in the precompetitive domain that aid in the scientific evaluation of the efficacy and safety of new therapies.
The Next Amyloidosis Forum Meeting
Wednesday, October 23, 2024Add To Calendar
We look forward to seeing you at the next meeting of the Amyloidosis Forum in October of 2024, whether you’ll be joining us in person at the FDA’s White Oak Campus, or online via Zoom.